MSD launches cancer drug Keytruda in India

By: |
New Delhi | September 13, 2017 5:36 PM

The launch follows receipt of regulatory approvals to launch the drug in India for treatment of unresectable or metastatic melanoma.

US-based drug major MSD today said it has launched cancer drug Keytruda in India for treatment of advanced melanoma, a form of skin cancer. (Represtative photo: Reuters)

US-based drug major MSD today said it has launched cancer drug Keytruda in India for treatment of advanced melanoma, a form of skin cancer. The launch follows receipt of regulatory approvals to launch the drug in India for treatment of unresectable or metastatic melanoma. “Keytruda is a breakthrough immuno-oncology therapy which we have launched for the treatment of advanced melanoma in India in line with our comprehensive approach to fostering patient access for approved indications,” an MSD spokesperson said in an e-mailed statement.

The spokesperson did not elaborate on pricing of the medicine. “Specifically, for advanced melanoma, we are introducing Keytruda with an India-specific price and Patient Access Program to assist patients who otherwise could not afford treatment,” the spokesperson said. However, according to industry sources, the maximum retail price (MRP) of one vial of Keytruda for a 21-day course is kept at Rs 2.36 lakh. MSD said its role as a global healthcare firm is first and foremost to discover and develop innovative medicines and vaccines that treat and prevent unmet medical needs. “We also recognise that we have a role to play – in partnership with other key stakeholders – in helping to ensure our products are accessible and affordable to those in need,” the spokesperson said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.